A targeted approach for thecontrol of hypertension
At Mineralys Therapeutics we are focused on developing medicines to target diseases driven by abnormally elevated aldosterone.
Hypertension has resulted in an estimated average of $130 billion annual economic burden in the United States alone between 2003 and 2014
Controlling hypertension is critical to reducing cardiovascular and renal disease; yet over 30 million hypertensive patients in the United States are unable to achieve their BP goal despite treatment.
Recent studies have demonstrated that elevated aldosterone production is prevalent in over 25% of all hypertensive patients.
Elevated aldosterone levels drive blood volume and blood pressure while also causing inflammatory and fibrotic increases leading to higher risk of stroke, kidney damage and heart failure.
By normalizing aldosterone levels, we believe lorundrostat can provide an effective and more targeted approach for the control of hypertension.
The SolutionTargeting the underlying cause of hypertension
Lorundrostat is a highly selective aldosterone synthase inhibitor developed to address abnormally elevated aldosterone, an underlying cause prevalent in at least 25% of all hypertensive patients.
Lorundrostat has demonstrated selectivity for the reduction of aldosterone with no cortisol suppression. Lorundrostat selectivity holds the potential for targeted treatment of blood pressure in hypertension patients with abnormally elevated aldosterone
Lorundrostat has demonstrated compelling clinical results, and once-daily dosing flexibility and was well tolerated profile in a recently completed phase 2 clinical trial.
November 16, 2022
Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101…
“We are very pleased to report that the Target-HTN trial met its primary and secondary endpoints, with MLS-101 demonstrating substantial placebo-adjusted reduction…
June 8, 2022
Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing…
Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension,…